Sign up to receive ATOTW weekly -

Similar documents
Coagulation Mechanisms Dr. Nervana Bayoumy

Adv Pathophysiology Unit 4 Page 1 of 10. Learning Objectives for this file:

General Principles of. Hemostasis. Kristine Krafts, M.D.

Hemostasis and Thrombosis

Introduction Hemostasis: Tourniquet Test & Bleeding Time. Hematology-Immunology System Faculty of Medicine Universitas Padjadjaran LOGO

Hemostasis. by Mohie-Aldien Elsayed

Department of medical physiology 3 rd week

Physiology Unit 3 HEMATOLOGY

Ch 13: Blood. What does blood do? Transport: Regulation: Protection:

These handouts are only meant as a guide while you follow the presentation on the screen. Sometimes the speaker will change some of the slides.

Local vasoconstriction. is due to local spasm of the smooth muscle (symp. reflex) can be maintained by platelet vasoconstrictors

BLOOD COAGULATION. 1. The initial phase of the process is vascular constriction. This limits the flow of blood to the area of injury.

Methods of Biomaterials Testing. Special Biology: Blood & Vessel

Dr. Suzana Voiculescu

LABORATORY APPROACH TO BLEEDING DISORDERS DR NISHANTH PG 1 ST YEAR DEPARTMENT OF PATHOLOGY

COAGULATION: BASIC PRINCIPLES. Peyman Eshghi Prof. of Pediatric Hematology & Oncology

HaematologY. Dr Tom Bate Again!

Chapter 19b Blood, cont d

Special Coagulation - APC Resistance. DiaPharma Group, Inc. Customer Service: Technical Support:

Laboratory investigation in the Bleeding Patient. Dr Craig Taylor Consultant Haematologist May 2016

Enzyme Research Laboratories product list 2018

Rheological and biochemical analyses on blood coagulation ~ Discovery of a new pathway under stagnant flow conditions ~

Biochemistry of connective tissue Pathochemistry of inflammation

The Cardiovascular System: Blood

Haemostasis. The function of haemostasis is: to prevent blood loss from injured vessels. to stop bleeding. to prevent thrombosis

Using TEG in the ED, OR, and ICU. Don H. Van Boerum, MD, FACS

Coagulation Cascade. TF-VIIa. Tissue Factor + VII. XIIa. Prothrombin. XIa. IXa. VIIIa. Thrombin. XL- Fibrin. XIII Monomer. Fibrinogen.

Pharmacology Lecture 5. Anticoagulants

Haemostasis Reagents product list 2018

CHROMOGENIC SUBSTRATE TECHNOLOGY. Giovanni Russi

2013 Health Press Ltd.

Immunomodulation at Cardiac Surgery. William T McBride MD

The Role Of Point of Care Coagulation Testing (POCCT) in Patient Blood Management. Elham Khalaf Adeli

Basic coagulation applications and case studies

P. W. HOWIE M.D., M.R.C.O.G. first method of activation is the intrinsic system. Hageman factor, which in turn activates a series of

Evolution of the Clotting Cascade. Kalyan Banda MD Hematology Fellows Conference 01/13/2017

Case 1. Case 1. Case 2. Case 2. Review of Bleeding Disorders Case 1

LABORATORY DIAGNOSIS OF BLEEDING DISORDERS

Overview of Anatomy and Physioloy II Second Year Students

Rheological Properties of Fibrin Clots

Session 1 Topics. Vascular Phase of Hemostasis. Coagulation Pathway. Action of Unfractionated Heparin. Laboratory Monitoring of Anticoagulant Therapy

Primary hemostasis. Vascular endothelium Vasoconstriction : local tissue factor, nervous system

Serine Proteases and their Inhibitors

proteins. The ECs are supported by a collagen-rich

Improving Outcomes of Cardiac Surgery with a Point-of-Care Based Transfusion Algorithm

Common Inherited Bleeding Disorders

The Coagulation Workup In The Office Setting

The effects of hypothermia and acidosis on Haemostasis

Westmead Hospital XENOTRANSPLANTATION Making Pigs Fly

Coagulation. Coagulation Limited CGL, CGDF Surveys & Anatomic Pathology Education Programs. Coagulation 117

Dr. Susan Louw Haematopathologist NHLS / WITS / SASTH

*NCCT is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. Program, provider #122.

Cell-Extracellular Matrix Interactions

De l'utilisation de la microscopie intravitale pour étudier la thrombose in vivo et tester de nouveaux médicaments antithrombotiques- 1er partie

Inhibition of Plasmin Generation in Plasma by Heparin, Low Molecular Weight Heparin. and a Covalent Antithrombin-Heparin Complex (ATH)

Bivalirudin (Angiomax ) vs. Heparin during Peripheral Vascular Interventions: Which is Better and How to Decide?

Scholars Research Library

Disclosures. I have received research funding from: I have received consulting fees/honoraria from: Novo Nordisk CSL-Behring Boehringer Ingelheim

Hematology Emergencies: Problems with Platelets

Table of Contents. Introduction. Worldwide Market and Technology Overview

Drugs used in Thromboembolic Disease. Munir Gharaibeh, MD, PhD, MHPE Department of Pharmacology Faculty of Medicine October 2014

Coagulation in perspective: Blood management. Objectives

COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)

Disclaimer: this is a very big topic and coverage will be only superficial.

Anticlotting mechanisms 1: physiology and pathology

Transfusion & Non-transfusion Approaches to Bleeding

BNG 331 Cell-Tissue Material Interactions. Wound Healing I

(B) Comparable expression of major integrin subunits and glycoproteins on the surface of resting WT and Lnk -/- platelets.

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

Endothelium conference

Plasma Testing in the Clinical Coagulation Laboratory: New drugs, new problems.

Blood 101. Dr. Karen L. Dallas. Medical Director, Hematopathology & Transfusion Medicine Providence Health Care

Regulation of the protein C anticoagulant pathway by C4b-binding protein. Robbert van de Poel

An Analysis of the Robustness and Fragility of the Coagulation System

Veins Valves prevent engorgement and backflow. Baroreceptor reflex. Veins returning blood

JOURNAL OF UNDERGRADUATE RESEARCH IN ALBERTA (JURA), VOL. 1, JULY An Agent-Based Simulation of Blood Coagulation Processes

Evaluation of the Bleeding Patient

THE EFFECT OF THAWING FRESH FROZEN PLASMA AT VARIOUS TEMPERATURES ON IN VITRO COAGULATION FACTOR ACTIVITY

Index. Autoimmune thrombocytopenic purpura (AITP), 100, 102, 105, 108, 187 Automated platelet counters, , 108

Common Inherited Coagulation Disorders. Inherited Coagulation Disorders. All coagulation factors and platelets in circulation (unactivated)

HEMOCOMPATIBILITY AND ENDOTHELIALIZATION OF ELASTIN AND COLLAGEN SCAFFOLDS: THE ROLE OF PLASMA PROTEINS, SHEAR STRESS AND INTEGRINS

THE HAEMOSTATIC DEFECT OF CARDIOPULMONARY BYPASS

Hemostasis practice: state-of-the-art

Sysmex Educational Enhancement and Development No

Haemostasis Antibodies

CONTRACTING ORGANIZATION: University of Texas Southwestern Medical Center Dallas, TX

Linking in silico and in vitro experiments to identify and evaluate a biomarker for enoxaparin activity

Haemostasis Antibodies

Cardiovascular (connective tissue)

2 Thomas G. DeLoughery

High Throughput Screening of Clopidogrel Resistance Using Microfluidic Technology

Dr. Vivien Chen [FINAL REPORT: KANEMATSU Final report for Vivien Chen: Kanematsu Memorial Award Outcomes:

Sysmex Educational Enhancement and Development No

Protein Therapeutics. Novo Nordisk Måløv. Outline

EDUCATIONAL COMMENTARY D-DIMER UPDATE

ab Factor VIIIa Activity Assay Kit (Fluorometric)

Substrates of Factor XIII-A: roles in thrombosis and wound healing

ROZAIMAH ZAIN-HAMID. Department of Pharmacology and Therapeutics Faculty of Medicine, Universitas Sumatera Utara

What is an Aptamer? smallest unit of repeating structure

Acute Traumatic Coagulopathy

Transcription:

BLOOD PHYSIOLOGY PART 2 ANAESTHESIA TUTORIAL OF THE WEEK 231 11 TH JULY 2011 Dr Karen Hayes Royal Devon & Exeter Correspondence to: kmhayes@hotmail.co.uk QUESTIONS Before continuing, try to answer the following questions. The answers can be found at the end of the article. 1. What are the three phases of cell based coagulation? 2. Which factor is primarily responsible for the generation of low levels of thrombin, serving to prime the vascular system to respond immediately to any tissue damage? 3. Which factor is responsible for converting fibrinogen to fibrin? a. Factor IXa b. TF/Factor VIIa complex c. Thrombin d. Factor Xa 4. What are the stages of the formation of a platelet plug? INTRODUCTION This is the second of two tutorials on blood physiology for the anaesthetist and will describe the complex processes involved in the control of haemorrhage. HAEMOSTASIS Haemostasis refers to the complex physiological processes that serve to minimise and arrest blood loss from a damaged blood vessel. These processes include the vessel s intrinsic response to damage or trauma, the formation of a platelet plug and the complex mechanism of coagulation. Response of the vasculature The initial response of a blood vessel to trauma is vasoconstriction, which is effective in reducing the volume of blood lost. Contraction of smooth muscle in vessels such as arterioles and venules is thought to be due to the depolarization of smooth muscle cells. Vasoactive mediators such as thromboxane A 2 and serotonin released from the vascular endothelium and activated platelets respectively, are also believed to contribute to vasoconstriction. Capillaries cannot contract, but their endothelial cells are able to adhere to one another, thereby sealing small gaps. Damage to the endothelial lining of vessels also results in the release of tissue factor, which is important in the coagulation process, and von Willebrand factor (vwf), which is vital for adhesion of platelets. ATOTW 231 Blood Physiology Part 2 11/07/2011 Page 1 of 5

Cell-based model of coagulation There are three distinct phases in the cell-based model of coagulation, namely initiation, amplification and propagation. Initiation This process is constantly occurring in tissues at a low level and serves to keep the vascular system primed to respond immediately to any tissue damage. This low level tissue factor (TF) pathway activity occurs outside the vascular compartment. TF is found on many interstitial cells and these cell surfaces provide the sites for initiation. Factors VII, X and prothrombin are able to diffuse from the intravascular compartment into the interstitial space and bind with TF, resulting in the generation of small amounts of thrombin. The amount of thrombin generated is not sufficient to lead to widespread clot formation as the vessel wall serves to act as a barrier to other essential cellular components. Amplification Damage to blood vessels results in the exposure of TF on sub-endothelial cells. The thrombin generated by these cells comes into contact with the platelets at the site of injury, resulting in these platelets becoming fully activated. It is also involved in the activation of other clotting factors, namely: factor V, and factor XI. Factor V is released by activated platelets and cleaves factor VIII from vwf, which activates vwf. Factor XI binds to the surfaces of activated platelets. The net result of this process is that the platelets are coated in activated coagulation factors. Propagation Factor IXa is generated by the TF/Factor VIIa complex located on the surface of TF-expressing cells. By combining with its co-factor, VIIIa on the surface of the platelets, factor IXa is responsible for activating factor X. The activation of factor X to factor Xa results in the combination of Xa with its cofactor Va, which in turn leads to the production of large quantities of thrombin. Thrombin then converts fibrinogen into fibrin. The fibrin structure of the clot is then stabilized by covalent bonding under the influence of factor XIII (Fig. 1). Figure 1. Cell based model of coagulation (1) initiation (2) amplification ( 3) propagation ATOTW 231 Blood Physiology Part 2 11/07/2011 Page 2 of 5

Formation of the platelet plug Platelet Structure Platelets are small, anucleate discs approximately 2-3micrometer in size. The structure of the platelet plays a fundamental part in its function. It has an external glycocalyx which contains membrane glycoproteins which are essential for adhesion and aggregation, The phospholipid bilayer located within the plasma membrane is important for providing for the phospholipid derived factors: platelet activating factor, arachidonic acid and platelet factor 3. A canalicular system invaginates both the platelet membrane and the microtubular skeleton. The latter lies beneath the membrane and provides a large area for adsorption of clotting factors. The cytoplasm also contains elements which serve to enhance platelet function, such as alpha granules, dense granules and dense tubules. Alpha granules contain vwf, platelet factor 4, fibrinogen and fibronectin, whilst dense granules contain ADP, ATP and pyrophosphate. Dense tubules provide the site for prostaglandin and thromboxane synthesis. Von Willebrand Factor Von Willebrand factor is located in the alpha granules of platelet cytoplasm. It acts as a bridging molecule between the platelet and the site of injury, facilitating the adherence of the platelet to the site. By forming a non-covalent complex with factor VIII it also serves to stabilize and prevent the rapid removal of factor VIII from the circulation. Adhesion Damage to the blood vessel results in the rapid migration of platelets to the site of injury in a non energy requiring process. Glycoprotein Ia facilitates adhesion to collagen. Further adhesion is enhanced by the binding of glycoprotein Ib-IX to the vwf-endothelial complex, which in turn exposes the GP- IIb-GP-IIIa complex, leading to the binding of vwf, fibrinogen and fibronectin. The net result is that the endothelial surface is covered by platelets. Platelet Activation Platelets are activated by collagen adhesion, the release of agonists such as ADP and adrenaline, and the generation of thrombin during the coagulation process. Platelets de-granulate due to the actions of thrombin and exposure to collagen. The release of both dense and alpha granules further facilitates platelet activation, adhesion and aggregation. Aggregation & Stabilisation This occurs as a result of the release of thromboxane A 2 and ADP, which promote platelet aggregation at the site of injury. This process of aggregation itself leads to further release of thromboxane A 2 and ADP, thus further enhancing aggregation. The release of fibrinogen and vwf from the alpha granules also contributes to more adhesion and aggregation. The collection of adherent platelets is stabilized by thrombospondin, another product of the degranulation of the alpha granules. This aggregate of platelets is then reinforced with a fibrin mesh (Fig. 2) ATOTW 231 Blood Physiology Part 2 11/07/2011 Page 3 of 5

Figure 2 Platelet (1) adhesion (2) activation (3) aggregation (4) stabilisation Regulation of coagulation On initiation of the coagulation process, mechanisms which inhibit coagulation are simultaneously induced. This is to prevent widespread, unabated clot formation. Control of Thrombin Levels There are three main regulatory mechanisms: 1. The maintenance of circulating thrombin in its inactive form 2. The inhibition of the activation of factors VIII and V by Proteins C and S 3. The specific inhibition of thrombin by: Anti-thrombin III, Alpha 2 - macroglobulin, Heparin cofactor II, Alpha 1 trypsin By controlling the production and activity of thrombin the formation of the fibrin clot can be limited. Fibrinolysis This is the process in which the fibrin clot is dissolved. The proteolytic enzyme plasmin plays an integral role in this process by breaking down the fibrin mesh. Plasminogen is the precursor of plasmin and binds to the fibrin within the clot during its formation. Both tissue plasminogen activator (t-pa) and urokinase stimulate the conversion of plasminogen to plasmin. t-pa is released several days after the initial injury by the endothelium and urokinase is found in the plasma. ATOTW 231 Blood Physiology Part 2 11/07/2011 Page 4 of 5

ANSWERS TO QUESTIONS 1. Initiation, amplification, propagation 2. Tissue Factor 3. c 4. Adhesion, activation, aggregation & stabilisation ACKNOWLEDGEMENTS Many thanks to Mr David Wilkinson for drawing the illustrations in figures 1 and 2. REFERENCES AND FURTHER READING Brandis K. The Physiology Viva. Questions and Answers. Australia. Australia Print and Copy. 2003. Guyton, A; Hall J. Textbook of Medical Physiology. London. W.B. Saunders. 1996 Ed: Petersen O. Lecture Notes: Human Physiology. Oxford. Blackwell Publishing. 2009 Ed: Spoors C, Kiff K. Training in Anaesthesia the essential curriculum. Oxford. Oxford University Press. 2010 ATOTW 231 Blood Physiology Part 2 11/07/2011 Page 5 of 5